VERS.L Regulatory News (VERS)

Press release May 2, 2018

Verseon Corporation

("Verseon" or the "Company")

Verseon presents new efficacy results on oral diabetic macular edema drug candidate at vision and ophthalmology conference

Fremont, Calif.-Verseon, a technology-based pharmaceutical company employing a computer-driven platform to develop a diverse drug pipeline, presented new efficacy results from its diabetic macular edema program at the Association for Research in Vision and Ophthalmology 2018 annual meeting in Honolulu this week. The preclinical data show that Verseon's oral plasma kallikrein inhibitors successfully reduce retinal leakage and retinal thickness, two hallmarks of the disease.

Diabetic macular edema (DME) is a leading cause of blindness in diabetics. In DME, chronically high blood sugar can weaken blood vessels in the eye and cause fluids to leak. Fluid accumulating in the macula (the central region of the retina) can result in swelling, blurred vision, and eventually central vision loss. The current standard of care for DME includes regular injections into the eye of repurposed anticancer agents or corticosteroids, treatments associated with side effects such as inflammation and infection.

Verseon's Dr. Melissa Calton presented comprehensive preclinical data for one of Verseon's new, potent and selective small-molecule plasma kallikrein inhibitors, VE-3539. In contrast to current DME drugs, Verseon's compound shows pharmacokinetics suitable for oral administration. Results from a well-established efficacy model, the retinal vascular permeability model, show that VE‑3539 successfully reduces retinal leakage and restores mean circulation times. "VE-3539 is the first orally dosed plasma kallikrein inhibitor to demonstrate efficacy in this preclinical model of DME," said Dr. Calton. Additionally, Verseon's candidate is efficacious in another widely used model of DME, the human plasma kallikrein injection model, that mimics the retinal thickening observed in patients.

"Verseon's DME drugs could offer a safe and convenient alternative to intravitreal injections," said Dr. Calton. "With their oral route of administration, our drug candidates are especially well-suited for prophylaxis, providing an important benefit for the growing number of diabetics who are at risk of losing their eye sight through DME."

About Verseon's diabetic macular edema program

Verseon has developed a new class of potent, selective compounds for the treatment of diabetic macular edema. The Company's plasma kallikrein inhibitors target a validated pathway addressing an underlying cause of the disease. In contrast to current injectable DME drugs, Verseon's inhibitors show pharmacokinetics suitable for oral administration in preclinical testing. Several lead candidates have also demonstrated efficacy in reducing retinal thickening and retinal leakage, two hallmarks of the disease, when administered orally.

About Verseon

Verseon Corporation (www.verseon.com, AIM: VSN) is a technology-based pharmaceutical company that pairs a proprietary, computational drug discovery platform with a comprehensive in-house chemistry and biology workflow to develop novel therapeutics that are unlikely to be found using conventional methods. The Company is applying its platform to a growing drug pipeline and currently has four active drug programs in the areas of anticoagulation, diabetic macular edema, hereditary angioedema, and oncology. The anticoagulation program is scheduled to enter phase I clinical trials in 2018.

-Ends-

For further information, please contact

For financial and business media enquiries, please contact

For trade and pharma media enquiries, please contact

Forward-Looking Statements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook," and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions, and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors.